|Videos|November 26, 2013
Episode 11 - Personalized Medicine in CRPC
Advertisement
Episodes in this series
During this segment, the panelists explore the use of personalized medicine in castration-resistant prostate cancer.
Jeffrey D. Dunn, PharmD, MBA, and Raoul S. Concepcion, MD, explain that clinicians hope to have better data available in the future to provide definitive answers about treatment options for specific patient populations.
Dr Concepcion explains the variables that are being reviewed to help clinicians make wiser treatment decisions for their patients.
However, E. David Crawford, MD, reminds the panelists why achieving this goal will not be easy.
Advertisement
Related to this article
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5